Healing peptide comparisons

Direct side-by-side comparisons of the most-discussed research peptides for tissue repair and regeneration.

• BPC-157 vs TB-500

  BPC-157 and TB-500 are the two most-discussed research peptides in soft-tissue repair. They have overlapping interest areas — tendon, ligament, and vascular healing — but operate by different mechanisms and rest on quite different bodies of evidence.

• GHK-Cu vs TB-500

  GHK-Cu and TB-500 are sometimes grouped together as 'tissue-repair peptides', but the two operate at very different scales — GHK-Cu primarily as a transcriptional modulator of dermal fibroblasts, TB-500 primarily as a cell-migration peptide.

• KPV vs LL-37

  KPV and LL-37 occupy overlapping but distinct niches in the inflammation–antimicrobial peptide space. KPV is small, charge-neutral, and primarily anti-inflammatory; LL-37 is larger, cationic, and combines direct antimicrobial activity with broad immunomodulation.

• BPC-157 vs AOD-9604

  Both BPC-157 and AOD-9604 are discussed in the context of post-injury recovery, but they originate from very different research programmes and target different tissues.

• TB-500 vs Thymosin Beta-4

  TB-500 is widely described as a fragment of thymosin beta-4, but in the research-chemical market the molecular identity supplied under the TB-500 label is not always defined. This comparison clarifies the relationship between the synthetic research peptide and the endogenous parent molecule, and discusses which to choose for a given research question.

• KPV vs Larazotide

  KPV and larazotide are both studied for gut-barrier indications but operate at completely different points in the mucosal pathology cascade. KPV suppresses NF-κB-driven inflammatory cytokine release inside mucosal cells; larazotide blocks zonulin-receptor signalling at the apical tight junction. The two are mechanistically complementary rather than substitutes — and one has progressed to Phase IIb clinical trials while the other has not.

• Epitalon vs GHK-Cu

  Epitalon and GHK-Cu are both grouped under 'anti-aging' peptide research but address different biological axes. Epitalon is a synthetic tetrapeptide studied for telomerase upregulation and pineal-related effects; GHK-Cu is a naturally occurring copper-binding tripeptide with the deepest dermal regenerative evidence base of any non-prescription peptide ingredient.

• BPC-157 vs Larazotide

  BPC-157 and larazotide both have gut-healing applications but operate at completely different points in mucosal biology. BPC-157 supports mucosal angiogenesis and ulcer healing through a broad pro-regenerative profile; larazotide blocks zonulin-driven tight-junction disassembly to prevent paracellular antigen leak. The two can be studied independently or in combination for layered gut-barrier research.

• Ipamorelin vs Sermorelin

  Ipamorelin and sermorelin are the two most-studied GH-axis research peptides, but they activate the pituitary GH-release machinery through fundamentally different receptors. Ipamorelin is a GHRP-class compound acting on the ghrelin receptor (GHSR-1a); sermorelin is the prototype GHRH analogue acting on the GHRH receptor. The combination of one of each — the canonical 'sermorelin + ipamorelin' or 'CJC-1295 + ipamorelin' research protocols — exploits the synergy of dual-pathway pituitary activation that defines modern GH-secretagogue research.

• Semaglutide vs Tirzepatide

  Semaglutide and tirzepatide are the two most clinically significant incretin-pathway peptide drugs of the late 2020s. Both are MHRA-licensed for type-2 diabetes and chronic weight management, both are administered as once-weekly subcutaneous injections, both are products of similar peptide-engineering principles (Aib substitution for DPP-4 resistance, fatty-acid acylation for albumin binding). The fundamental pharmacological difference is receptor pharmacology: semaglutide is a selective GLP-1 receptor agonist; tirzepatide adds GIP receptor agonism for dual-receptor pharmacology. Head-to-head trials (SURPASS-2, SURMOUNT-5) confirm tirzepatide produces superior HbA1c reduction and weight loss at the maximum licensed doses of each.

• Semax vs Selank

  Semax and Selank are the two prototype Russian-developed research peptides for cognitive and behavioural applications — both developed by the Russian Institute of Molecular Genetics, both intranasally delivered short heptapeptides with C-terminal Pro-Gly-Pro stabilisation, both registered as prescription medicines in Russia but unlicensed in the UK. The principal differentiation is mechanism and intended pharmacology: Semax is primarily nootropic (BDNF/NGF upregulation, learning and memory effects); Selank is primarily anxiolytic (enkephalinase modulation, non-sedating anxiety reduction). The two are pharmacologically complementary rather than substitutes, and the canonical research-chemical-community protocol pairs them in combined intranasal use.

• Thymosin Alpha-1 vs Thymosin Beta-4

  Thymosin Alpha-1 and Thymosin Beta-4 share the historical 'thymosin' name because both were originally isolated from the same bovine thymic Fraction 5 preparation by Allan Goldstein's laboratory in the 1970s. Despite the naming, they are structurally, mechanistically, and pharmacologically distinct compounds addressing entirely different biological processes. Thymosin Alpha-1 is an immune-modulator; Thymosin Beta-4 is an actin-binding tissue-repair peptide. This comparison clarifies the differentiation that the confusing shared naming can obscure.

• Semaglutide vs Retatrutide

  Semaglutide is the licensed GLP-1 monoagonist that defined the modern incretin weight-loss category; retatrutide is Eli Lilly's Phase III triple GLP-1/GIP/glucagon agonist that has produced the highest weight-loss effect sizes documented for any pharmacological approach to obesity. Both target the incretin pathway but at fundamentally different scales of receptor coverage and development maturity.

• Ipamorelin vs Hexarelin

  Ipamorelin and hexarelin are both growth-hormone-releasing peptides (GHRPs) acting as GHSR-1a agonists at the ghrelin receptor. They differ substantially in selectivity, potency, receptor kinetics, and off-target profile — hexarelin is more potent and engages the cardiac CD36 receptor; ipamorelin is more selective for GHSR-1a and has cleaner off-target pharmacology.

• Humanin vs MOTS-c

  Humanin and MOTS-c are both mitochondrial-derived peptides (MDPs) — small peptides encoded within mitochondrial DNA that act as retrograde signalling molecules between mitochondria and nucleus. They arise from distinct mtDNA loci (16S rRNA for humanin, 12S rRNA for MOTS-c), engage distinct pathways (Bax/Bak inhibition vs AMPK activation), and produce distinct phenotypes (cytoprotection vs metabolic regulation).

• Matrixyl vs Argireline

  Matrixyl and argireline are the two most-visible cosmetic peptides on the ingredient-label market, both regulated as cosmetic ingredients rather than medicines in the UK. They operate by fundamentally different mechanisms — matrixyl through fibroblast stimulation of collagen and extracellular matrix synthesis, argireline through inhibition of SNARE-complex-mediated neurotransmitter release. The two are frequently combined in formulations, addressing wrinkle appearance through complementary rather than competing mechanisms.